

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings of claim in the application:

Claim 1 (currently amended): A method of delaying development of a lesion associated with papillomavirus infection in a mammal who has been exposed to papillomavirus, comprising administering a composition comprising a polynucleotide comprising an immunostimulatory sequence (ISS) to said mammal, wherein the ISS comprises the sequence 5'-C, G, pyrimidine, pyrimidine, C, G-3', wherein the polynucleotide is at least 8 and less than about 200 nucleotides in length, wherein the mammal is a human, and the papillomavirus is human papillomavirus (HPV), wherein a papillomavirus antigen is not administered in conjunction with administration of said composition, wherein said composition is administered at a site of exposure to papillomavirus, and wherein said composition is administered in an amount sufficient to delay development of a lesion associated with papillomavirus infection.

Claim 2 (original): The method of claim 1, wherein the ISS comprises the sequence 5'-purine, purine, C, G, pyrimidine, pyrimidine, C, G-3'.

Claim 3 (original): The method of claim 2, wherein the ISS comprises a sequence selected from the group consisting of 5'-AACGTTTCG-3', and 5'-GACGTTTCG-3'.

Claim 4 (original): The method of claim 1, wherein the ISS comprises the sequence 5'-TGACTGTGAACGTTTCGAGATGA-3' (SEQ ID NO:1).

Claim 5 (canceled)

Claim 6 (previously presented): The method of claim 1, wherein said site of exposure to papillomavirus is a wart, a papilloma, a condyloma, a neoplasia or a dysplasia.

Claims 7-8 (canceled)

Claim 9 (currently amended): A method of reducing severity of a lesion associated with papillomavirus infection in a mammal infected with papillomavirus, comprising administering a composition comprising a polynucleotide comprising an immunostimulatory sequence (ISS) to said mammal, wherein the ISS comprises the sequence 5'-C, G, pyrimidine, pyrimidine, C, G-3', wherein the polynucleotide is at least 8 and less than about 200 nucleotides in length, wherein the mammal is a human, and the papillomavirus is human papillomavirus (HPV), wherein a papillomavirus antigen is not administered in conjunction with administration of said composition, wherein said composition is administered at a papillomavirus-associated lesion, and wherein said composition is administered in an amount sufficient to reduce severity of a lesion associated with papillomavirus infection.

Claim 10 (original): The method of claim 9, wherein the ISS comprises the sequence 5'-purine, purine, C, G, pyrimidine, pyrimidine, C, G-3'.

Claim 11 (original): The method of claim 10, wherein the ISS comprises a sequence selected from the group consisting of 5'-AACGTTTCG-3' and 5'-GACGTTTCG-3'.

Claim 12 (original): The method of claim 9, wherein the ISS comprises the sequence 5'-TGACTGTGAACGTTTCGAGATGA-3' (SEQ ID NO:1).

Claim 13 (canceled)

Claim 14 (previously presented): The method of claim 9, wherein said lesion is a wart, a papilloma, a condyloma, a neoplasia or a dysplasia.

Claims 15-22 (canceled)

Claim 23 (previously presented): The method of claim 1, wherein the polynucleotide comprises a phosphate backbone modification.

Claim 24 (previously presented): The method of claim 23, wherein the phosphate backbone modification is a phosphorothioate.

Claim 25 (previously presented): The method of claim 9, wherein the polynucleotide comprises a phosphate backbone modification.

Claim 26 (previously presented): The method of claim 25, wherein the phosphate backbone modification is a phosphorothioate.

Claim 27 (cancelled)